

Question for written answer E-003997/2026

to the Commission

Rule 144

Leire Pajín (S&D), Nicolás González Casares (S&D), Lina Gálvez (S&D), Hana Jalloul Muro (S&D)

Subject: Lenzetto supply problems in several Member States

Lenzetto (transdermal estradiol), which is used in hormone replacement therapy to relieve menopause symptoms, has been affected by supply troubles and intermittent availability in a number of Member States. The shortages have created a spike in demand for alternative transdermal estradiol treatments – patches and gels in particular – and this in turn has put yet more pressure on supply.

Regulation (EU) 2022/123 provides for EU monitoring, prevention and coordination measures with regard to shortages of medicinal products, especially where they may affect several Member States and require coordination at Union level.

1. Is the Commission aware of the supply problems affecting Lenzetto? What does it make of the breadth of shortages throughout the EU?
2. Do the Commission and EMA have information on the Member States affected and the common reasons for the disruptions?
3. What steps does the Commission intend to take to improve continuity of supply and, where appropriate, to coordinate the action taken by national authorities and the manufacturer?

Submitted: 2.10.2026